Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Segment Information (Details) - USD ($) $ in Thousands	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Segment Reporting Information [Line Items]
Provision for income taxes	$ 261	$ 177	$ 870	$ 746
Net loss	198,147	319,771	419,824	499,275
Operating Segments \| Reportable Segment
Segment Reporting Information [Line Items]
Preclinical research programs R&D Expense	16,398	15,081	41,933	26,944
R&D personnel expense (excluding share-based compensation)	20,490	17,889	41,627	37,202
R&D Share-based compensation expense	13,110	7,071	48,344	28,362
R&D Knopp amendment expense	0	171,850	0	171,850
G&A personnel expense (excluding share-based compensation)	6,004	6,122	12,478	12,510
G&A Share-based compensation expense	7,702	5,161	25,530	18,747
Other segment items	20,706	15,195	37,660	27,368
Non-operating income	(13,815)	(14,178)	(14,308)	(18,483)
Provision for income taxes	261	177	870	746
Net loss	198,147	319,771	419,824	499,275
Operating Segments \| BHV-4157 (Troriluzole) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	14,245	17,076	28,033	34,163
Operating Segments \| BHV-2000 (Taldefgrobep Alfa) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	8,045	17,748	14,229	28,876
Operating Segments \| BHV-7000 & BHV-7010 (Kv7) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	31,172	27,400	62,744	52,204
Operating Segments \| BHV-2100 (TRPM3 Antagonist) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	6,845	4,272	23,594	8,892
Operating Segments \| BHV-8000 (TYK2/JAK1) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	21,216	2,675	25,589	6,925
Operating Segments \| BHV-1300 (IgG Degrader) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	11,732	7,358	20,352	16,583
Operating Segments \| BHV-1310 (IgG Degrader) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	3,612	3,938	4,686	7,199
Operating Segments \| BHV-1400 (IgA Degrader) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	6,737	7,612	11,597	11,704
Operating Segments \| BHV-1600 (β1-AR AAB Degrader) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	1,806	3,009	4,809	3,825
Operating Segments \| BHV-1510 (TROP-2) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	5,384	3,043	9,873	22,628
Operating Segments \| BHV-1530 (FGFR3) \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	15,393	0	18,569	0
Operating Segments \| Other R&D program expense \| Reportable Segment
Segment Reporting Information [Line Items]
Direct R&D program expense	1,104	1,272	1,615	1,030
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
Segment Reporting Information [Line Items]
Net loss	$ 0	$ 0	$ 0	$ 0

Biohaven Ltd. 10-Q